专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07358350B2 Oncogene, recombinant protein derived therefrom, and uses thereof 有权
标题翻译：癌基因，从其衍生的重组蛋白及其用途
公开(公告)号：US07358350B2
公开(公告)日：2008-04-15
申请号：US10758562
申请日：2004-01-16
申请人： Akira Saito , Masahiko Kuroda
发明人： Akira Saito , Masahiko Kuroda
IPC分类号： C07H21/02 , C07H21/04
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.
摘要翻译：本发明鉴定了来自人的新型致癌基因的总核苷酸序列，其直接参与由宫颈上皮细胞的HPV感染诱导的宫颈癌和由此编码的致癌蛋白的氨基酸序列的癌变机制，提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。具体地，本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列。 ID。 1，特别是SEQ ID NO：1的核苷酸序列的多核苷酸。 ID。 2号

2. 发明申请

US20110213128A1 SIRNA CAPABLE OF INHIBITING THE EXPRESSION OF AN ONCOGENE INVOLVED IN CERVICAL CANCER 审中-公开
标题翻译： SIRNA能够抑制癌症参与肿瘤的表达
公开(公告)号：US20110213128A1
公开(公告)日：2011-09-01
申请号：US13005198
申请日：2011-01-12
申请人： Akira SAITO , Masahiko Kuroda
发明人： Akira SAITO , Masahiko Kuroda
IPC分类号： C07K16/32 , C07K14/435
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ ID NO: 1, particularly a polynucleotide of the nucleotide sequence of SEQ ID NO: 2.
摘要翻译：本发明鉴定了来自人的新型致癌基因的总核苷酸序列，其直接参与由宫颈上皮细胞的HPV感染诱导的宫颈癌和由此编码的致癌蛋白的氨基酸序列的癌变机制，提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。具体地，本发明提供了涉及宫颈癌发展的人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列，特别是SEQ ID NO：2的核苷酸序列的多核苷酸。

3. 发明申请

US20090042830A1 NOVEL ONCOGENE, RECOMBINANT PROTEIN DERIVED THEREFROM, AND USES THEREOF 有权
标题翻译：新型重组蛋白，其衍生的蛋白质及其用途
公开(公告)号：US20090042830A1
公开(公告)日：2009-02-12
申请号：US12207298
申请日：2008-09-09
申请人： Akira SAITO , Masahiko Kuroda
发明人： Akira SAITO , Masahiko Kuroda
IPC分类号： A61K31/713 , C07K14/435 , C07K16/00 , A61P35/00 , G01N33/574 , C07H21/02
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No. 1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No. 2.
摘要翻译：本发明鉴定了来自人的新型致癌基因的全部核苷酸序列，其直接涉及由HPV感染宫颈上皮细胞诱导的宫颈癌及其编码的致癌蛋白的氨基酸序列的癌化机制，提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。具体地，本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列。 ID。特别是SEQ ID NO：1的核苷酸序列的多核苷酸。 ID。第2号。

4. 发明申请

US20120115139A1 METHOD FOR EVALUATING CANCER 审中-公开
标题翻译：癌症评估方法
公开(公告)号：US20120115139A1
公开(公告)日：2012-05-10
申请号：US13265680
申请日：2010-04-21
申请人： Masahiko Kuroda , Akira Saito , Maki Sano
发明人： Masahiko Kuroda , Akira Saito , Maki Sano
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.
摘要翻译：提供了一种使用新型癌症标志物评价受试者的癌症的发病，临床前期，临床阶段或预后的癌症评价方法。使用至少一种选自hsa-miR-92和hsa-miR-494的miRNA作为癌症评价中的新型癌症标志物。检测细胞或组织样品中的癌症标志物，并根据癌症标志物的表达水平评估样品中癌症的可能性。根据该评价方法，通过检测miRNA作为癌症标记物，可以以极好的可靠性来评价样品中癌症的可能性。作为检测癌症标记物的方法，优选使用例如相对于被固定化的样品的标记探针进行原位杂交法。

5. 发明授权

US07432358B2 Oncogene, recombinant protein derived therefrom, and uses thereof 有权
公开(公告)号：US07432358B2
公开(公告)日：2008-10-07
申请号：US11449671
申请日：2006-06-09
申请人： Akira Saito , Masahiko Kuroda
发明人： Akira Saito , Masahiko Kuroda
IPC分类号： C07K16/00
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.

6. 发明授权

US07893246B2 Sirna capable of inhibiting the expression of an oncogene involved in cervical cancer 有权
标题翻译： Sirna能够抑制参与宫颈癌的癌基因的表达
公开(公告)号：US07893246B2
公开(公告)日：2011-02-22
申请号：US12207298
申请日：2008-09-09
申请人： Akira Saito , Masahiko Kuroda
发明人： Akira Saito , Masahiko Kuroda
IPC分类号： C07H21/04 , C12N15/11
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No. 1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No. 2.
摘要翻译：本发明鉴定了来自人的新型致癌基因的全部核苷酸序列，其直接涉及由HPV感染宫颈上皮细胞诱导的宫颈癌及其编码的致癌蛋白的氨基酸序列的癌化机制，提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。具体地，本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列。 ID。特别是SEQ ID NO：1的核苷酸序列的多核苷酸。 ID。第2号。

7. 发明申请

US20060217342A1 Novel oncogene, recombinant protein derived therefrom, and uses thereof 有权
标题翻译：癌基因，从其衍生的重组蛋白及其用途
公开(公告)号：US20060217342A1
公开(公告)日：2006-09-28
申请号：US11449671
申请日：2006-06-09
申请人： Akira Saito , Masahiko Kuroda
发明人： Akira Saito , Masahiko Kuroda
IPC分类号： A61K48/00 , G01N33/574 , C07H21/02 , C07K14/82 , C07K16/30
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produded recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.
摘要翻译：本发明鉴定了来自人的新型致癌基因的总核苷酸序列，其直接参与由宫颈上皮细胞的HPV感染诱导的宫颈癌和由此编码的致癌蛋白的氨基酸序列的癌变机制，提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。具体地，本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列。 ID。 1，特别是SEQ ID NO：1的核苷酸序列的多核苷酸。 ID。 2号

8. 发明授权

US08632967B2 Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent 有权
标题翻译：癌症标记，通过使用癌症标记物评估癌症的方法和评估试剂
公开(公告)号：US08632967B2
公开(公告)日：2014-01-21
申请号：US13472190
申请日：2012-05-15
申请人： Masahiko Kuroda , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
发明人： Masahiko Kuroda , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要翻译：本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

9. 发明申请

US20100062978A1 METHOD FOR INHIBITING SIGNAL TRANSDUCTION, SIGNAL TRANSDUCTION INHIBITOR TO BE USED THEREIN AND USE THEREOF 有权
标题翻译：用于抑制信号传输的方法，其使用的信号传输抑制剂及其用途
公开(公告)号：US20100062978A1
公开(公告)日：2010-03-11
申请号：US12294347
申请日：2007-03-23
申请人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
发明人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
IPC分类号： A61K38/16 , C12N5/08 , C07H21/00 , C07K14/00 , C07K7/08 , A61K31/7088 , C12Q1/68 , A61P35/00
CPC分类号： G01N33/57484 , A61K38/00 , A61K48/00 , C07K14/47 , C12N9/1205 , C12Q1/6886 , C12Q2600/106 , G01N2800/52 , Y10S435/96 , Y10S435/968
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供抑制人细胞中erbB1或erbB2介导的信号传导途径的活化的方法和用于其的信号传导抑制剂。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。可以将上述多肽直接引入细胞，或将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于erbB1和erbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

10. 发明授权

US08173365B2 Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof 有权
标题翻译：抑制信号转导的方法，其中使用的信号转导抑制剂及其用途
公开(公告)号：US08173365B2
公开(公告)日：2012-05-08
申请号：US12294347
申请日：2007-03-23
申请人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
发明人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： G01N33/57484 , A61K38/00 , A61K48/00 , C07K14/47 , C12N9/1205 , C12Q1/6886 , C12Q2600/106 , G01N2800/52 , Y10S435/96 , Y10S435/968
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供抑制人细胞中erbB1或erbB2介导的信号传导途径的活化的方法和用于其的信号传导抑制剂。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。可以将上述多肽直接引入细胞，或将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于erbB1和erbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式